首页> Rheumatology and therapy> Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Lars Erik,Kristensen

第一单位： The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57 Road 8, Entrance 19, 2000, Frederiksberg, Copenhagen, Denmark. lars.erik.kristensen@regionh.dk.

作者： Lars Erik,Kristensen ^[1] ; Mauro,Keiserman ^[2] ; Kim,Papp ^[3] ; Leslie,McCasland ^[4] ; Douglas,White ^[5] ; Kyle,Carter ^[6] ; Ralph,Lippe ^[6] ; Huzefa,Photowala ^[6] ; Leonidas,Drogaris ^[6] ; Ahmed M,Soliman ^[6] ; Michael,Chen ^[6] ; Byron,Padilla ^[6] ; Frank,Behrens ^[7]

作者单位： The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57 Road 8, Entrance 19, 2000, Frederiksberg, Copenhagen, Denmark. lars.erik.kristensen@regionh.dk. ^[1] Rheumatology Section, Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil. ^[2] Probity Medical Research and Alliance Clinical Trials, Waterloo, ON, Canada.;Department of Medicine, University of Toronto, Toronto, ON, Canada. ^[3] Arthritis and Rheumatism Associates, LLC, Jonesboro, AR, USA. ^[4] Rheumatology Department, Waikato Hospital, Hamilton, New Zealand.;Waikato Clinical School, University of Auckland, Auckland, New Zealand. ^[5] AbbVie Inc, North Chicago, IL, USA. ^[6] Rheumatology, Immunology, Inflammation Medicine, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Goethe University, Frankfurt Am Main, Germany. ^[7]

关键词 IL-23 KEEPsAKE?1 Long-term treatment Psoriatic arthritis Risankizumab csDMARD-IR

DOI 10.1007/s40744-024-00654-5

PMID 38498141

发布时间 2024-06-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Rheumatology and therapy

2024年11卷3期

617-632页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Rheumatology and therapy

2024年11卷3期

617-632页

检索历史清除

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

Rheumatology and therapy

相似文献

同项目论文

Rheumatology and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

Rheumatology and therapy

相似文献

同项目论文

Rheumatology and therapy

相关期刊

检索历史清除